MedTrace Logo

Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes

NCT07096037 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-08-01

No results posted yet for this study

Summary

The primary objective of this clinical trial is to evaluate the efficacy and safety of a topical Urtica dioica cataplasm in managing knee pain and functional limitations in athletic children diagnosed with Osgood-Schlatter Disease. Efficacy will be assessed through changes in knee pain using the Visual Analog Scale (VAS) and functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Three groups will be tested:

* UDC Group: topical application of Urtica dioica cataplasm
* Standard Care Group: oral vitamin D supplementation and physical rest
* Placebo Group: topical application of a placebo cataplasm using Beta vulgaris subsp. cicla

Conditions

  • Osgood-Schlatter Disease

Interventions

OTHER

Urtica dioica cataplasm

Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period.

OTHER

Placebo

Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use.

DRUG

Vitamin D

Participants will receive oral vitamin D.

BEHAVIORAL

Resting conditions

Reduction in physical activity based on orthopedic advice.

Sponsors & Collaborators

  • Faculty of Medicine, Sousse

    lead OTHER

Principal Investigators

  • Amira Zairi · Department of Biochemistry, Faculty of Medicine of Sousse, University of Sousse, Tunisia

  • Sahbi El Mtaoua · Department of Physical Medicine and Rehabilitation, Hospital Ibn Jazzar of Kairouan, University of Sousse, Tunisia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
15 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2025-09-15
Completion
2026-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07096037 on ClinicalTrials.gov